Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Albert Roger

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Expert Review of Pharmacoeconomics & Outcomes Research|June 10, 2010
Patient assessment of onset of action and overall satisfaction with ebastine fast-dissolving tablets in allergic rhinitisAlbert Roger, Josep Fortea, Sheila Mora, et al.
International Archives of Allergy and Immunology|January 19, 2023
Using Component-Resolved Diagnosis to Characterize the Sensitization to Specific Cat and Dog Allergens in Patients with Allergic Respiratory Diseases in Catalonia, SpainAlbert Roger, Carlota Lazo, Noelia Arias, et al.
Immunity, Inflammation and Disease|November 18, 2014
A novel and well tolerated mite allergoid subcutaneous immunotherapy: evidence of clinical and immunologic efficacyAlbert Roger, Nathalie Depreux, Yani Jurgens, et al.
Trials|May 28, 2025
Efficacy and safety of a house dust mites allergoid in patients with allergic rhinitis-PROACAROS study: protocol for a randomized controlled trialInmaculada Buendía-Jiménez, María Matas-Ros, Teresa Garriga-Baraut, et al.
International Archives of Allergy and Immunology|July 29, 2010
Observational study of the safety of an ultra-rush sublingual immunotherapy regimen to treat rhinitis due to house dust mitesAlbert Roger, José-Luis Justicia, Luis Ángel Navarro, et al.
Immunotherapy|July 9, 2016
A novel microcrystalline tyrosine-adsorbed, mite-allergoid subcutaneous immunotherapy: 1-year follow-up reportAlbert Roger, Nathalie Depreux, Yanina Jurgens, et al.
Allergologia Et Immunopathologia|June 6, 2006
Acceptance survey of a fast dissolving tablet pharmaceutical formulation in allergic patients. Satisfaction and expectanciesAlbert Roger Reig, M Josep Plazas Fernández, Jordi Galván Cervera, et al.
Clinicoeconomics and Outcomes Research : CEOR|September 24, 2016
A budget impact analysis of Spiromax(®) compared with Turbuhaler(®) for the treatment of moderate to severe asthma: a potential improvement in the inhalation technique to strengthen medication adherence could represent savings for the Spanish Healthcare System and five Spanish regionsJosep Darbà, Gabriela Ramírez, Juan L García-Rivero, et al.
Drugs - Real World Outcomes|February 16, 2021
A Retrospective Nationwide Non-Interventional Study of an Aqueous Sublingual Immunotherapy Formulation Administered with a 200-µL Dosing PumpAlbert Roger Reig, Clara Padró Casas, Diego Gutiérrez Fernández, et al.
Current Pharmaceutical Design|January 17, 2018
Immunotheraphy in Allergic DiseasesAlbert Roger, Maria Basagana, Aina Teniente-Serra, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Expert Review of Pharmacoeconomics & Outcomes Research|June 10, 2010
Patient assessment of onset of action and overall satisfaction with ebastine fast-dissolving tablets in allergic rhinitisAlbert Roger, Josep Fortea, Sheila Mora, et al.
International Archives of Allergy and Immunology|January 19, 2023
Using Component-Resolved Diagnosis to Characterize the Sensitization to Specific Cat and Dog Allergens in Patients with Allergic Respiratory Diseases in Catalonia, SpainAlbert Roger, Carlota Lazo, Noelia Arias, et al.
Immunity, Inflammation and Disease|November 18, 2014
A novel and well tolerated mite allergoid subcutaneous immunotherapy: evidence of clinical and immunologic efficacyAlbert Roger, Nathalie Depreux, Yani Jurgens, et al.
Trials|May 28, 2025
Efficacy and safety of a house dust mites allergoid in patients with allergic rhinitis-PROACAROS study: protocol for a randomized controlled trialInmaculada Buendía-Jiménez, María Matas-Ros, Teresa Garriga-Baraut, et al.
International Archives of Allergy and Immunology|July 29, 2010
Observational study of the safety of an ultra-rush sublingual immunotherapy regimen to treat rhinitis due to house dust mitesAlbert Roger, José-Luis Justicia, Luis Ángel Navarro, et al.
Immunotherapy|July 9, 2016
A novel microcrystalline tyrosine-adsorbed, mite-allergoid subcutaneous immunotherapy: 1-year follow-up reportAlbert Roger, Nathalie Depreux, Yanina Jurgens, et al.
Allergologia Et Immunopathologia|June 6, 2006
Acceptance survey of a fast dissolving tablet pharmaceutical formulation in allergic patients. Satisfaction and expectanciesAlbert Roger Reig, M Josep Plazas Fernández, Jordi Galván Cervera, et al.
Clinicoeconomics and Outcomes Research : CEOR|September 24, 2016
A budget impact analysis of Spiromax(®) compared with Turbuhaler(®) for the treatment of moderate to severe asthma: a potential improvement in the inhalation technique to strengthen medication adherence could represent savings for the Spanish Healthcare System and five Spanish regionsJosep Darbà, Gabriela Ramírez, Juan L García-Rivero, et al.
Drugs - Real World Outcomes|February 16, 2021
A Retrospective Nationwide Non-Interventional Study of an Aqueous Sublingual Immunotherapy Formulation Administered with a 200-µL Dosing PumpAlbert Roger Reig, Clara Padró Casas, Diego Gutiérrez Fernández, et al.
Current Pharmaceutical Design|January 17, 2018
Immunotheraphy in Allergic DiseasesAlbert Roger, Maria Basagana, Aina Teniente-Serra, et al.
Pageof 2